Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Other Non Operating Income (2016 - 2019)

RedHill Biopharma has reported Other Non Operating Income over the past 6 years, most recently at -$8000.0 for Q4 2019.

  • Quarterly Other Non Operating Income rose 99.64% to -$8000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was -$344000.0 through Dec 2019, down 230.77% year-over-year, with the annual reading at -$344000.0 for FY2019, 230.77% down from the prior year.
  • Other Non Operating Income was -$8000.0 for Q4 2019 at RedHill Biopharma, down from -$5000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $1.7 million in Q3 2017 and troughed at -$3.9 million in Q4 2017.
  • The 5-year median for Other Non Operating Income is -$201000.0 (2016), against an average of -$507066.7.
  • Year-over-year, Other Non Operating Income crashed 527.86% in 2017 and then skyrocketed 2046.0% in 2019.
  • A 5-year view of Other Non Operating Income shows it stood at -$248000.0 in 2015, then tumbled by 312.1% to -$1.0 million in 2016, then tumbled by 277.59% to -$3.9 million in 2017, then surged by 43.2% to -$2.2 million in 2018, then soared by 99.64% to -$8000.0 in 2019.
  • Per Business Quant, the three most recent readings for RDHL's Other Non Operating Income are -$8000.0 (Q4 2019), -$5000.0 (Q3 2019), and -$1.3 million (Q2 2019).